reports
Cytori Strengthens Global Intellectual Property Portfolio with Key Pat...
SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) (“Cytori” or the “Company”) announced today the issuance of a number of key patents that strengthen its intellectual property portfolio in the U.S. and Europe. Cytori now has over 90 global patents issued and another 55 patent applications pending around the globe. Several of Cytori’s recently-issued patents contain claims providing protections for Cytori’s program in the use of Cytori Cell Therapy™ for treating scleroderma. Cytori recently completed enrollme...
Cytori Granted FDA Orphan Drug Designation for ECCS-50 in Scleroderma
SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted Cytori an orphan drug designation for cryopreserved or centrally processed ECCS-50 for scleroderma. “This orphan drug designation is part of our long-term strategy to facilitate the autologous retreatment of patients with scleroderma, if it is needed,” said Dr. Marc Hedrick, President and CEO of Cytori Therapeutics. “Our development plan for cryopreserved ECCS-50...
Cytori Reports Third Quarter 2016 Business and Financial Results
SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics (NASDAQ: CYTX) (“Cytori” or the “Company”) today announced its third quarter financial results and provided updates on its corporate activity and clinical development. Third quarter 2016 net loss allocable to common stockholders was $5.4 million and $0.26 per share. Operating cash burn was approximately $4.6 million in the third quarter 2016. Cytori ended the third quarter of 2016 with approximately $15 million of cash and cash equivalents. Selected Recent Highl...
Cytori to Present Data in Two Distinct Models of Impaired Wound Healin...
SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) will present new preclinical data describing positive effects of Cytori Cell Therapy™ on a corneal wound healing model and in cutaneous scarring following burn injury. The data will be presented at the International Federation for Adipose Therapeutics (IFATS) in San Diego on November 17-20, 2016. One presentation is titled “Adipose-Derived Regenerative Cells Promote Proliferation of Corneal Epithelial Cell And Corneal Wound Healing.” This presentatio...
Cytori to Webcast Third Quarter Financial Results on November 9
SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its third quarter financial results and business update on Wednesday, November 9, 2016 at 5:30 PM Eastern Time. The dial-in information is as follows: Dial-In Number: +1.877.402.3914Conference ID: 9218454 Prior to the webcast at approximately 4:15 PM Eastern Time on November 9, Cytori will issue its third quarter earnings release which will review Cytori’s third quarter performance. The webcast will be availa...
Cytori Presents Scleroderma Clinical Trial Data at the 2016 American C...
SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) will present data from its STAR Phase 3 clinical trial describing progress, preliminary blinded patient characteristics, and safety of adipose-derived regenerative cells (ADRCs) for treatment of scleroderma hand dysfunction (clinicaltrials.gov) at the Annual Meeting of the American College of Rheumatology on November 15, 2016. The poster presentation will describe the STAR clinical trial procedures, patient characteristics, and preliminary blinded sa...
Cytori Publication on Cytori Cell Therapy for Combined Radiation and T...
SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today the publication of preclinical safety and efficacy study data using Cytori Cell Therapy™ for combined radiation and thermal injury. This preliminary study was performed with support from the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services. The paper, entitled “Development of a Combined Radiatio...
BARDA Increases Contract Option with Cytori to Advance Countermeasure ...
SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics (NASDAQ: CYTX) (the “Company”) today announced that the Company and Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, increased the contract option originally signed in August 2014 to fund continued investigation and development of Cytori Cell Therapy™ for use in thermal burn injuries. The amended option is valued at $16.6 million, an increase of approximately $2.5 million from its previous val...
QuickView: Scleroderma therapy efficacy maintained
Recent data suggest the therapeutic benefits following a single administration of Cytori's ADRCs can persist for at least one year in patients with scleroderma-associated impaired hand function (SAIHF). Pivotal studies in SAIHF and urinary incontinence are underway.
QuickView: Focused on clinical cell therapies
After raising over $25m through equity/warrant financings and extending the debt maturity, Cytori can focus on its late-stage R&D programmes. Its ADRC therapy clinical trials in scleroderma and knee osteoarthritis aim to show that the implantation of patient-derived cells can improve functional outcomes.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.